Compare CVU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVU | EDSA |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 51.5M |
| IPO Year | 1996 | 2018 |
| Metric | CVU | EDSA |
|---|---|---|
| Price | $4.21 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 56.0K | ★ 3.1M |
| Earning Date | 11-16-2026 | 12-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $69,262,124.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.29 | $0.72 |
| 52 Week High | $5.98 | $20.32 |
| Indicator | CVU | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 34.03 |
| Support Level | $3.60 | $0.72 |
| Resistance Level | $5.30 | $4.10 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 4.72 | 10.03 |
CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States. It also provides engineering, program management, supply chain management and kitting, and Maintenance Repair and Overhaul (MRO) services. CPI also acts as a subcontractor to prime aircraft manufacturers in the production of commercial aircraft parts. CPI Aero supplies the E-2D Advanced Hawkeye surveillance aircraft, the A-10 Thunderbolt attack jet, the Gulfstream G650, the UH-60 BLACK HAWK helicopter, and the S-92 helicopter, and others.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.